Skip Nav Destination
1-7 of 7
Shun-Ichi Kimura, Yuhei Nakamura, Masakatsu Kawamura, Junko Takeshita, Shunto Kawamura, Nozomu Yoshino, Yukiko Misaki, Kazuki Yoshimura, Shimpei Matsumi, Ayumi Gomyo, Yosuke Okada, Yu Akahoshi, Masaharu Tamaki, Machiko Kusuda, Kazuaki Kameda, Hidenori Wada, Miki Sato, Aki Tanihara, Hideki Nakasone, Shinichi Kako, Yoshinobu Kanda
Acta Haematol (2022) 145 (4): 404–411.
Published Online: 19 January 2022
... or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Acute myeloid leukemia Relapse Neutropenia Cytarabine D-index High-dose...
Biao Wu, Zhengwei Jenny Mao, Zhi Wang, Pin Wu, Hongyu Huang, Wenjun Zhao, Lei Zhang, Zhou Zhang, Hongchao Yin, Robert Peter Gale, Bin Yin
Acta Haematol (2021) 144 (5): 534–541.
Published Online: 24 February 2021
...Biao Wu; Zhengwei Jenny Mao; Zhi Wang; Pin Wu; Hongyu Huang; Wenjun Zhao; Lei Zhang; Zhou Zhang; Hongchao Yin; Robert Peter Gale; Bin Yin Resistance to cytarabine is an important cause of therapy failure in persons with acute myeloid leukemia (AML). Deoxycytidine kinase, encoded by DCK , catalyzes...
Acta Haematol (2017) 137 (4): 195–200.
Published Online: 27 April 2017
...Hongyu Zhao; Li Xu; Yongjian Yang; Jianhua Shao; Ping Chen; Xuebin Dong; Linping Gu; Daqi Li Aims: To investigate the safety and efficacy of the triple therapy of decitabine, idarubicin, and cytarabine in the treatment of refractory or recurrent acute myeloid leukemia (R/R AML). Methods: We...
Dan Gong, Wei Li, Liang-Ding Hu, Jian-Liang Shen, Mei-Yun Fang, Qing-Ming Yang, Heng-Xiang Wang, Xiao-Yan Ke, Hui-Ren Chen, Zhao Wang, Hui Liu, Feng Liu, Yi-Gai Ma, Jing-Wen Wang, Hong-Hua Li, Quan-Shun Wang, Yu Jing, Xiao-Ning Gao, Li-Ping Dou, Yong-Hui Li, Jian-Min Luo, Li Yu
Acta Haematol (2016) 136 (4): 201–209.
Published Online: 17 September 2016
...: The survival of patients with acute myeloid leukemia (AML) with t(8;21) was reported to be shorter in China than in other countries. Patients: We analyzed the correlation between different cytarabine (Ara-c) regimens and outcome in 255 t(8;21) AML patients in China who received postremission consolidation...
Acta Haematol (2014) 131 (4): 202–207.
Published Online: 27 November 2013
...Ibrahim Aldoss; Lingyun Ji; Mintallah Haider; Vinod Pullarkat We retrospectively reviewed the outcome of 20 consecutive subjects with refractory/relapsed acute myeloid leukemia (AML; 9 refractory and 11 relapsed) treated at our institution with a fludarabine, cytarabine and etoposide (FCE) salvage...
Acta Haematol (2004) 112 (3): 121–125.
Published Online: 03 September 2004
..., instructions or products referred to in the content or advertisements. Cisplatin Cytarabine Lymphoma Topotecan Original Paper Acta Haematol 2004;112:121 125 DOI: 10.1159/000079721 Received: September 1, 2003 Accepted after revision: February 2, 2004 Topotecan, Ara-C, Cisplatin and Prednisolone...
Acta Haematol (1998) 99 (3): 133–137.
Published Online: 11 April 1998
... cytarabine. Intensification of induction treatment with etoposide or high-dose cytarabine does not appear to alter the CR rate but prolongs remission and has some impact on survival. High-dose cytarabine in induction combinations increase relapse-free survival compared to standard approaches. These induction...